SG11202007072RA - Chemokine receptor modulators and uses thereof - Google Patents
Chemokine receptor modulators and uses thereofInfo
- Publication number
- SG11202007072RA SG11202007072RA SG11202007072RA SG11202007072RA SG11202007072RA SG 11202007072R A SG11202007072R A SG 11202007072RA SG 11202007072R A SG11202007072R A SG 11202007072RA SG 11202007072R A SG11202007072R A SG 11202007072RA SG 11202007072R A SG11202007072R A SG 11202007072RA
- Authority
- SG
- Singapore
- Prior art keywords
- chemokine receptor
- receptor modulators
- modulators
- chemokine
- receptor
- Prior art date
Links
- 102000009410 Chemokine receptor Human genes 0.000 title 1
- 108050000299 Chemokine receptor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Electrically Operated Instructional Devices (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622771P | 2018-01-26 | 2018-01-26 | |
| US201862772027P | 2018-11-27 | 2018-11-27 | |
| US201862784161P | 2018-12-21 | 2018-12-21 | |
| PCT/US2019/015023 WO2019147862A1 (en) | 2018-01-26 | 2019-01-24 | Chemokine receptor modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007072RA true SG11202007072RA (en) | 2020-08-28 |
Family
ID=66286951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007072RA SG11202007072RA (en) | 2018-01-26 | 2019-01-24 | Chemokine receptor modulators and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10683280B2 (en) |
| EP (1) | EP3743418B1 (en) |
| JP (2) | JP7355758B2 (en) |
| KR (1) | KR102860287B1 (en) |
| CN (1) | CN111971279B (en) |
| AU (1) | AU2019212478C1 (en) |
| BR (1) | BR112020015056A2 (en) |
| CA (1) | CA3089380A1 (en) |
| DK (1) | DK3743418T3 (en) |
| ES (1) | ES2989617T3 (en) |
| FI (1) | FI3743418T3 (en) |
| HU (1) | HUE069276T2 (en) |
| IL (1) | IL276295B2 (en) |
| MX (1) | MX2020007812A (en) |
| PL (1) | PL3743418T3 (en) |
| PT (1) | PT3743418T (en) |
| RU (1) | RU2020128176A (en) |
| SG (1) | SG11202007072RA (en) |
| TW (1) | TWI826416B (en) |
| WO (1) | WO2019147862A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202007072RA (en) | 2018-01-26 | 2020-08-28 | Rapt Therapeutics Inc | Chemokine receptor modulators and uses thereof |
| CN113727758A (en) * | 2019-03-01 | 2021-11-30 | 锐新医药公司 | Bicyclic heterocyclic compounds and use thereof |
| KR20230005938A (en) * | 2020-04-30 | 2023-01-10 | 이도르시아 파마슈티컬스 리미티드 | Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators |
| CN111732572B (en) * | 2020-07-31 | 2020-11-13 | 苏州国匡医药科技有限公司 | Preparation method of chiral antitumor drug FLX475 and intermediate thereof |
| AU2022216216A1 (en) * | 2021-02-02 | 2023-08-03 | Rapt Therapeutics, Inc. | Methods of making trans isomeric forms of G protein-coupled receptor modulators |
| CN115466244B (en) * | 2021-06-10 | 2024-08-02 | 武汉伯瑞恒医药科技有限公司 | Chemokine receptor CCR4 antagonists, intermediates, methods of preparation, pharmaceutical compositions and uses thereof |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| KR20240090695A (en) | 2021-10-26 | 2024-06-21 | 이도르시아 파마슈티컬스 리미티드 | CCR6 receptor regulator |
| AR127486A1 (en) * | 2021-10-28 | 2024-01-31 | Idorsia Pharmaceuticals Ltd | CCR6 RECEIVER MODULATORS |
| WO2023143194A1 (en) * | 2022-01-25 | 2023-08-03 | 瑞石生物医药有限公司 | Ccr4 small molecule antagonist and use thereof |
| EP4504338A1 (en) * | 2022-04-06 | 2025-02-12 | RAPT Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
| JP2025518244A (en) | 2022-06-02 | 2025-06-12 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | Heterocyclic CCR4 inhibitors and their uses |
| WO2024114568A1 (en) * | 2022-11-28 | 2024-06-06 | 上海美悦生物科技发展有限公司 | Heterocyclic substituted pyrimidine compound, preparation method therefor, and use thereof |
| TWI879384B (en) * | 2023-01-16 | 2025-04-01 | 大陸商上海美悅生物科技發展有限公司 | Heterocyclic substituted pyrazine compound and preparation method and use thereof |
| CN121002023A (en) * | 2023-04-24 | 2025-11-21 | 浙江华海药业股份有限公司 | Chemokine receptor modulators and methods of use |
| CN121039119A (en) * | 2023-05-02 | 2025-11-28 | 奥瑞基尼肿瘤有限公司 | Fused bicyclic heterocyclyl compounds as CCR4 modulators |
| WO2024236538A1 (en) * | 2023-05-17 | 2024-11-21 | Aurigene Oncology Limited | Azetidine linked bicyclic heterocyclyl compounds as ccr4 modulators |
| TW202517627A (en) | 2023-07-12 | 2025-05-01 | 美商瑞佩特治療公司 | Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof |
| CN119638669A (en) * | 2023-09-15 | 2025-03-18 | 上海医药集团股份有限公司 | A chemokine receptor antagonist, pharmaceutical composition and application |
| WO2025098425A1 (en) * | 2023-11-09 | 2025-05-15 | 浙江华海药业股份有限公司 | Chemokine receptor modulator preparation method and use |
| TW202523327A (en) * | 2023-11-14 | 2025-06-16 | 大陸商上海美悅生物科技發展有限公司 | Spiroheterocyclic compound, preparation method, intermediate and use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
| JP2594486B2 (en) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | Topical ophthalmic composition |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| PT880508E (en) | 1996-02-13 | 2003-07-31 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| WO2001092224A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
| TWI328007B (en) | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
| TW200305395A (en) | 2002-03-15 | 2003-11-01 | Novartis Ag | Organic compounds |
| US7790884B2 (en) * | 2006-03-24 | 2010-09-07 | Astellas Pharma Inc. | Acylaminopiperidine compound |
| JP2010208945A (en) * | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | Heterocyclic compound |
| JP2009007341A (en) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition |
| CN102388039B (en) | 2009-02-26 | 2015-07-15 | 葛兰素集团有限公司 | Pyrazole derivatives useful as CCR4 receptor antagonists |
| RS57219B1 (en) | 2010-03-10 | 2018-07-31 | Incyte Holdings Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| WO2013082490A1 (en) | 2011-12-01 | 2013-06-06 | Chemocentryx, Inc. | Substituted anilines as ccr(4) antagonists |
| CA2856831C (en) | 2011-12-01 | 2020-02-18 | Chemocentryx, Inc. | Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists |
| NZ750182A (en) * | 2016-07-29 | 2023-03-31 | Rapt Therapeutics Inc | Chemokine receptor modulators and uses thereof |
| KR20200104291A (en) * | 2017-11-06 | 2020-09-03 | 랩트 테라퓨틱스, 인크. | Anticancer drugs |
| SG11202007072RA (en) | 2018-01-26 | 2020-08-28 | Rapt Therapeutics Inc | Chemokine receptor modulators and uses thereof |
-
2019
- 2019-01-24 SG SG11202007072RA patent/SG11202007072RA/en unknown
- 2019-01-24 KR KR1020207023897A patent/KR102860287B1/en active Active
- 2019-01-24 MX MX2020007812A patent/MX2020007812A/en unknown
- 2019-01-24 EP EP19719655.3A patent/EP3743418B1/en active Active
- 2019-01-24 PL PL19719655.3T patent/PL3743418T3/en unknown
- 2019-01-24 JP JP2020561599A patent/JP7355758B2/en active Active
- 2019-01-24 ES ES19719655T patent/ES2989617T3/en active Active
- 2019-01-24 RU RU2020128176A patent/RU2020128176A/en unknown
- 2019-01-24 WO PCT/US2019/015023 patent/WO2019147862A1/en not_active Ceased
- 2019-01-24 FI FIEP19719655.3T patent/FI3743418T3/en active
- 2019-01-24 US US16/256,987 patent/US10683280B2/en active Active
- 2019-01-24 CA CA3089380A patent/CA3089380A1/en active Pending
- 2019-01-24 HU HUE19719655A patent/HUE069276T2/en unknown
- 2019-01-24 CN CN201980022286.4A patent/CN111971279B/en active Active
- 2019-01-24 AU AU2019212478A patent/AU2019212478C1/en active Active
- 2019-01-24 DK DK19719655.3T patent/DK3743418T3/en active
- 2019-01-24 BR BR112020015056-8A patent/BR112020015056A2/en unknown
- 2019-01-24 IL IL276295A patent/IL276295B2/en unknown
- 2019-01-24 PT PT197196553T patent/PT3743418T/en unknown
- 2019-01-25 TW TW108102924A patent/TWI826416B/en active
-
2020
- 2020-04-27 US US16/859,896 patent/US11384064B2/en active Active
- 2020-04-27 US US16/859,951 patent/US11192879B2/en active Active
-
2022
- 2022-05-20 US US17/750,165 patent/US12098139B2/en active Active
-
2023
- 2023-09-20 JP JP2023152057A patent/JP2023179513A/en active Pending
-
2024
- 2024-08-19 US US18/808,638 patent/US20250059167A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276295A (en) | Chemokine receptor modulators and uses thereof | |
| ZA201900961B (en) | Chemokine receptor modulators and uses thereof | |
| IL276330A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IL276332B2 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IL272599A (en) | Pyruvate kinase modulators and use thereof | |
| ZA201807731B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IL286107A (en) | Spiro-lactam nmda receptor modulators and usesthereof | |
| IL264514B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IL264488A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| ZA202105847B (en) | Mtroc modulators and uses thereof | |
| PL3853218T3 (en) | Somatostatin modulators and uses thereof | |
| ZA202101273B (en) | Heteroaromatic nmda receptor modulators and uses thereof | |
| EP3143005A4 (en) | Chemokine cxcr4 and ccr5 receptor modulators and used related thereto | |
| ZA201905513B (en) | Rorgamma modulators and uses thereof | |
| ZA201905511B (en) | Rorgamma modulators and uses thereof | |
| HUE068738T2 (en) | Novel selective ackr3 modulators and uses thereof | |
| HK40040004A (en) | Chemokine receptor modulators and uses thereof |